- In January 2022, Betta Pharmaceuticals received regulatory approval for Icotinib for the treatment of non-small cell lung cancer (NSCLC) in China. This approval marks a significant milestone in expanding treatment options for NSCLC patients in the region. Icotinib, an EGFR inhibitor, is expected to enhance the availability of targeted therapies for patients with EGFR-mutated lung cancer in China
- In June 2022, Takeda Oncology introduced Brigatinib for the treatment of non-small cell lung cancer (NSCLC) in Poland. This launch expands access to a new, targeted therapy for NSCLC patients, particularly those with EGFR mutations. Brigatinib offers a promising treatment option, enhancing the available therapies for lung cancer patients in Poland
- In December 2022, Jiangsu Hansoh Pharmaceutical submitted a pre-registration application for Aumolertinib for the treatment of non-small cell lung cancer (NSCLC) in the European Union. This step marks a significant move towards making Aumolertinib available to NSCLC patients in the EU. The drug, an EGFR inhibitor, aims to provide a targeted treatment option for patients with EGFR mutations in the region
